David Stokoe

机构：Enzo Life Sciences (United States), Calico Life Sciences · ORCID：0000-0002-6333-5364

发表论文 272 篇 · 总被引 24862 次 · h-index 63

代表论文

• Structure of the p53 degradation complex from HPV16 (2024 · Nature Communications · 被引 62)
• Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint (2024 · Immunity · 被引 26)
• Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex (2024 · Communications Chemistry · 被引 10)
• BiDAC-dependent degradation of plasma membrane proteins by the endolysosomal system (2025 · Nature Communications · 被引 6)
• Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1 -Mutant Lung Cancer (2025 · Cancer Research · 被引 2)
• Targeting NRF2 addiction in cancer: synthetic lethal strategies beyond direct inhibition (2026 · Frontiers in Cell and Developmental Biology · 被引 1)